ICER is here to stay so how best can industry engage for its benefit?
The Institute for Clinical and Economic Review (ICER) is gaining a growing reputation with US payers. While ICER's drug assessments are advisory, and many will point to perceived weaknesses in its processes and methodology, the organization is becoming ever more influential in shaping stakeholder discussions and payer negotiations. ICER has signalled its willingness to work with manufacturers when assessing drugs, so how can pharma best engage and what can they contribute?
Whether you see ICER as an irritant or a force for good it is an established part of the US market landscape and manufacturers need clear strategies for engaging with, or responding to, ICER drug assessments. To help you shape your ICER strategy we interviewed, in April and May 2020, pharma industry experts with direct ICER experience. In Engaging with ICER: Lessons and insights for pharma they outline the key issues and opportunity/danger areas plus the practical constructive steps pharma can take.
Experts explore key questions such as...
What Experts say...
"Manufacturers can also proactively try to figure out what the ICER for the particular product is and what is likely to be their recommendation. They can then try to be close to the ICER assessment so that discussions with payers can be faster. Manufacturers want to make sure that they are not too far off the ICER assessment, and that way they can do better in discussion with payers."
Executive Director, Market Access
"We reach out immediately and say 'how can we help?' Now we have relationships with them, so they reach out to us as well. We let them know upfront that we want to help them, we want to participate, we want to have the best outcomes for patients. Maybe they have a question or are struggling with something around the methodology, and they're now more open to reaching out and asking for expertise. In the last review they had some off schedule calls with us."
Chief Medical Officer
"We gain from engagement with ICER, we are showing the good science of our product and the value of our product. That's our job, to whoever needs to understand the science behind our products, we need to make sure that the full picture of our products is represented."
Senior Manager, HEOR
What to expect
A detailed report exploring pharma's attitude to and progressive strategies for engaging with, or responding to, ICER assessments:
Expert contributors
Experts contributing to this report have been screened to ensure they:
Interview questions were informed by in-depth secondary research.
Experts interviewed included
Experts provided their own individual views, which do not necessarily reflect the views of the organizations they work for.
Why choose FirstWord ExpertViews reports?
FirstWord's ExpertViews reports reveal the real world insights of knowledgeable experts to analyze in detail key commercial and market trends that pharma management need to understand if they are to effectively respond to critical developments. These highly-focussed reports:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved